Clinical and cytogenetic/molecular risk factors for post-MPN AML
| Risk factors . |
|---|
| Clinical |
| Age >60-65 y |
| Red blood cell transfusion dependency |
| Prior treatment exposure (pipobroman, 32P, chlorambucil, busulfan) |
| Prior thrombosis* |
| Myelofibrosis or prefibrotic ET/PV |
| Laboratory |
| Leukocytosis (>15 × 109/L to 30 × 109/L) |
| Anemia (Hgb <10 g/dL) |
| Thrombocytopenia (<50 × 109/L to 100 × 109/L) |
| Peripheral blast count (>1% to 10%) |
| Extreme thrombocytosis (>1000 × 109/L)* |
| Elevated serum IL-8† |
| Elevated serum C-reactive peptide† |
| Cytogenetics |
| Monosomal karyotype‡ |
| Complex karyotype or sole or 2 abnormalities that include +8, −7/7q, i(17q), −5/5q−, 12p−, inv(3), 11q23 rearrangement§ |
| Chromosome 17p deletion |
| Molecular |
| TP53, TET2, ASXL1, EZH2, SRSF2, IDH1/2, RUNX1, U2AF1Q157 |
| Risk factors . |
|---|
| Clinical |
| Age >60-65 y |
| Red blood cell transfusion dependency |
| Prior treatment exposure (pipobroman, 32P, chlorambucil, busulfan) |
| Prior thrombosis* |
| Myelofibrosis or prefibrotic ET/PV |
| Laboratory |
| Leukocytosis (>15 × 109/L to 30 × 109/L) |
| Anemia (Hgb <10 g/dL) |
| Thrombocytopenia (<50 × 109/L to 100 × 109/L) |
| Peripheral blast count (>1% to 10%) |
| Extreme thrombocytosis (>1000 × 109/L)* |
| Elevated serum IL-8† |
| Elevated serum C-reactive peptide† |
| Cytogenetics |
| Monosomal karyotype‡ |
| Complex karyotype or sole or 2 abnormalities that include +8, −7/7q, i(17q), −5/5q−, 12p−, inv(3), 11q23 rearrangement§ |
| Chromosome 17p deletion |
| Molecular |
| TP53, TET2, ASXL1, EZH2, SRSF2, IDH1/2, RUNX1, U2AF1Q157 |